[144] Cardlytics, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 filing for Cardlytics, Inc. (CDLX) shows a proposed sale of 26,048 common shares through Fidelity Brokerage Services on 08/15/2025 with an aggregate market value of $31,695.21. The shares were acquired on 08/14/2025 via restricted stock vesting and were paid as compensation. The filing lists total shares outstanding of 53,236,901. The filer also reported two prior sales in the past three months: 26,217 shares sold on 05/15/2025 for $50,808.55 and 7,324 shares sold on 07/02/2025 for $13,055.76. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.

Positive

• Acquisition was via restricted stock vesting, indicating the shares were compensation rather than an external purchase
• Filer used Form 144, providing regulatory transparency about the intended sale under Rule 144

Negative

• Insider has made multiple recent sales in the past three months totaling 33,541 shares for $63,864.31
• Proposed sale of 26,048 shares shortly after vesting could be viewed as insider liquidity that investors may note

Insights

Securities Analyst

TL;DR Insider filing reports a planned sale of recently vested restricted stock and shows multiple recent insider sales.

The filing documents a proposed sale of 26,048 shares acquired the prior day via restricted stock vesting and designated as compensation. The use of Form 144 indicates the filer intends to rely on Rule 144 resale provisions for restricted/controlled securities. The filing also discloses two recent sales in the last three months totaling 33,541 shares for aggregate gross proceeds of $63,864.31. For investors, this is a routine compliance notice; it documents liquidity events by an insider but does not include any operational or financial performance data for the company itself.

Corporate Governance Expert

TL;DR This is a standard insider sale notice triggered by vesting; it raises routine governance transparency points.

The filing shows the insider received compensation through restricted stock vesting and promptly reported intent to sell under Rule 144. Repeated sales by the same individual within a short window are disclosed, which is important for transparency and for monitoring insider trading patterns. The document includes the required signer representation about lack of undisclosed material adverse information, but it provides no additional governance or plan adoption details (e.g., 10b5-1 plan dates) within the text.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	26048	31695.21	53236901	08/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/14/2025	Restricted Stock Vesting	Issuer			26048	08/14/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Alexis R. Desieno 675 Ponce de Leon Ave. NE Suite 4100 Atlanta GA 30308	Common	05/15/2025	26217	50808.55
Alexis R. Desieno 675 Ponce de Leon Ave. NE Suite 4100 Atlanta GA 30308	Common	07/02/2025	7324	13055.76

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for Cardlytics (CDLX) report?

The Form 144 reports a proposed sale of 26,048 common shares through Fidelity on 08/15/2025 with aggregate market value $31,695.21.

How were the 26,048 CDLX shares acquired?

The shares were acquired on 08/14/2025 via restricted stock vesting and the payment type is listed as compensation.

Did the filer sell other Cardlytics shares recently?

Yes. The filing discloses sales of 26,217 shares on 05/15/2025 for $50,808.55 and 7,324 shares on 07/02/2025 for $13,055.76.

How many Cardlytics shares are outstanding according to the filing?

The filing lists 53,236,901 shares outstanding.

Who is the broker handling the proposed sale?

The broker named is Fidelity Brokerage Services LLC, located at the address shown in the filing.